Evaluation of a Human BCG Challenge Model to Assess Antimycobacterial Immunity Induced by BCG and a Candidate Tuberculosis Vaccine, MVA85A, Alone and in Combination
Open Access
- 23 November 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 209 (8), 1259-1268
- https://doi.org/10.1093/infdis/jit647
Abstract
Background. A new vaccine is urgently needed to combat tuberculosis. However, without a correlate of protection, selection of the vaccines to take forward into large-scale efficacy trials is difficult. Use of bacille Calmette-Guérin (BCG) as a surrogate for human Mycobacterium tuberculosis challenge is a novel model that could aid selection. Methods. Healthy adults were assigned to groups A and B (BCG-naive) or groups C and D (BCG-vaccinated). Groups B and D received candidate tuberculosis vaccine MVA85A. Participants were challenged with intradermal BCG 4 weeks after those who received MVA85A. Skin biopsies of the challenge site were taken 2 weeks post challenge and BCG load quantified by culture and quantitative polymerase chain reaction (qPCR). Results. Volunteers with a history of BCG showed some degree of protective immunity to challenge, having lower BCG loads compared with volunteers without prior BCG, regardless of MVA85A status. There was a significant inverse correlation between antimycobacterial immunity at peak response after MVA85A and BCG load detected by qPCR. Conclusion. Our results support previous findings that this BCG challenge model is able to detect differences in antimycobacterial immunity induced by vaccination and could aid in the selection of candidate tuberculosis vaccines for field efficacy testing. Clinical Trials Registration NCT01194180.Keywords
This publication has 30 references indexed in Scilit:
- Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adultsVaccine, 2012
- A Human Challenge Model for Mycobacterium tuberculosis Using Mycobacterium bovis Bacille Calmette-GuérinThe Journal of Infectious Diseases, 2012
- Preclinical Development of an In Vivo BCG Challenge Model for Testing Candidate TB Vaccine EfficacyPLOS ONE, 2011
- Experimental human challenge infections can accelerate clinical malaria vaccine developmentNature Reviews Immunology, 2010
- Viral Booster Vaccines Improve Mycobacterium bovis BCG-Induced Protection against Bovine TuberculosisInfection and Immunity, 2009
- MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus MacaquesPLOS ONE, 2009
- Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge StudiesAmerican Journal of Epidemiology, 2008
- Boosting with Poxviruses Enhances Mycobacterium bovis BCG Efficacy against Tuberculosis in Guinea PigsInfection and Immunity, 2005
- Bactericidal Activity in Whole Blood as a Potential Surrogate Marker of Immunity after Vaccination against TuberculosisClinical and Vaccine Immunology, 2002
- A Whole Blood Bactericidal Assay for TuberculosisThe Journal of Infectious Diseases, 2001